Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL. The company operates in a single segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | Q1 2009 | Q1 2008 (Revised) |
|---|---|---|
| Total Revenues | $3,308 | $3,613 |
| Product Sales | $3,238 | $3,537 |
| Operating Income | $1,321 | $1,415 |
| Net Income | $1,019 | $1,100 |
| Diluted EPS | $0.98 | $1.01 |
| Operating Cash Flow | $859 | $1,582 |
| Cash & Marketable Securities | $10,378 | $9,552 (Dec 31, 2008) |
| Total Debt | $11,408 | $9,352 (Dec 31, 2008) |
Note: Q1 2008 figures are revised to reflect the retrospective adoption of FSP APB 14-1 regarding convertible debt accounting.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 8% year-over-year. Worldwide product sales fell 8%, driven by a 10% decline in U.S. sales and a 2% decline in international sales.
- Aranesp: Sales dropped 18% due to FDA-mandated label changes restricting use in supportive cancer care and reimbursement pressures.
- ENBREL: Sales dropped 20%, largely due to a one-time $120 million inventory stocking benefit in Q1 2008 and current economic conditions reducing demand.
- Neulasta/NEUPOGEN: Sales were relatively flat (-1%), with U.S. sales up 1% offset by international declines.
- Profitability: Net income decreased 7% to $1.019 billion. Operating expenses decreased 9% to $1.987 billion, aided by lower Wyeth profit share expenses ($57 million reduction) and lower staff-related costs.
- Accounting Change: Adoption of FSP APB 14-1 resulted in the bifurcation of convertible debt into debt and equity components, increasing reported interest expense and reducing net income by approximately $38 million for the quarter compared to pre-adoption figures.
- Debt Issuance: In January 2009, Amgen issued $2.0 billion in new long-term notes (2019 and 2039 Notes), increasing total debt.
Guidance, Outlook, and Risks
- Economic Environment: Management cites the global economic downturn as a significant headwind, leading to reduced patient access, higher co-pays, and lower wholesaler inventory levels.
- Regulatory Risks (ESAs): Ongoing scrutiny of Erythropoiesis-Stimulating Agents (ESAs) by the FDA and CMS poses risks. A proposed Risk Evaluation and Mitigation Strategy (REMS) could materially impact Aranesp sales. The company is conducting Study 782 to evaluate overall survival in cancer patients.
- Competition: ENBREL faces new competition from J&J's Simponi (approved April 2009). Biosimilar competition is increasing in Europe for Aranesp, Neulasta, and NEUPOGEN.
- Restructuring: The company has completed initial 2007 restructuring actions but estimates an additional $45 million to $90 million in costs for subsequent initiatives.
- Legal Proceedings: Significant litigation includes AWP pricing lawsuits, patent disputes (Roche, Ariad, Sensipar), and multiple Qui Tam (False Claims Act) investigations regarding marketing practices.
Investor Verification Checklist
- Accounting Impact: Verify the specific impact of FSP APB 14-1 on interest expense and net income to ensure accurate year-over-year comparisons.
- ESA Labeling & REMS: Monitor FDA decisions regarding the REMS program for ESAs and the results of the TREAT study and Study 782, as these directly impact Aranesp and EPOGEN revenue.
- Wholesaler Inventory: Assess the extent to which Q1 2009 sales declines were driven by temporary wholesaler destocking versus permanent demand destruction.
- Debt Maturity: Confirm the company's plan to repay the $1.0 billion 4.00% notes due in November 2009 without issuing new debt.
- Legal Exposure: Review the status of the Massachusetts Qui Tam Action and other False Claims Act investigations for potential financial liabilities.